KR20230061441A - Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도 - Google Patents

Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도 Download PDF

Info

Publication number
KR20230061441A
KR20230061441A KR1020237010791A KR20237010791A KR20230061441A KR 20230061441 A KR20230061441 A KR 20230061441A KR 1020237010791 A KR1020237010791 A KR 1020237010791A KR 20237010791 A KR20237010791 A KR 20237010791A KR 20230061441 A KR20230061441 A KR 20230061441A
Authority
KR
South Korea
Prior art keywords
raav
vegf
ser
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010791A
Other languages
English (en)
Korean (ko)
Inventor
광핑 가오
필립 타이
클라우디오 푼조
하이지앙 린
Original Assignee
유니버시티 오브 매사추세츠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 매사추세츠 filed Critical 유니버시티 오브 매사추세츠
Publication of KR20230061441A publication Critical patent/KR20230061441A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020237010791A 2020-09-03 2021-09-02 Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도 Pending KR20230061441A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074361P 2020-09-03 2020-09-03
US63/074,361 2020-09-03
US202163179700P 2021-04-26 2021-04-26
US63/179,700 2021-04-26
PCT/US2021/048917 WO2022051537A1 (en) 2020-09-03 2021-09-02 Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof

Publications (1)

Publication Number Publication Date
KR20230061441A true KR20230061441A (ko) 2023-05-08

Family

ID=80491540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010791A Pending KR20230061441A (ko) 2020-09-03 2021-09-02 Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도

Country Status (10)

Country Link
US (1) US20230340529A1 (https=)
EP (1) EP4208478A4 (https=)
JP (1) JP2023540094A (https=)
KR (1) KR20230061441A (https=)
AU (1) AU2021336425A1 (https=)
BR (1) BR112023003548A2 (https=)
CA (1) CA3192736A1 (https=)
IL (1) IL300864A (https=)
MX (1) MX2023002695A (https=)
WO (1) WO2022051537A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
AU2024247959A1 (en) * 2023-03-28 2025-10-09 General Medicines Llc Nucleic acid off-switches and methods and uses thereof
WO2024220389A2 (en) * 2023-04-17 2024-10-24 University Of Massachusetts Aav2 variants and uses thereof
CN119656336A (zh) * 2023-09-21 2025-03-21 成都弘基生物科技有限公司 一种重组腺相关病毒在制备治疗与血管新生相关眼病的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100897379B1 (ko) * 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
EP3134522B1 (en) * 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
US11046955B2 (en) * 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
AU2018227483A1 (en) * 2017-02-28 2019-09-12 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
US11103552B2 (en) * 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations

Also Published As

Publication number Publication date
MX2023002695A (es) 2023-05-19
WO2022051537A1 (en) 2022-03-10
EP4208478A4 (en) 2025-04-02
CA3192736A1 (en) 2022-03-10
EP4208478A1 (en) 2023-07-12
IL300864A (en) 2023-04-01
JP2023540094A (ja) 2023-09-21
US20230340529A1 (en) 2023-10-26
BR112023003548A2 (pt) 2023-04-04
AU2021336425A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
KR20230061441A (ko) Kh902 (콘베르셉트)의 전달을 위한 아데노-연관 바이러스 및 그의 용도
CN113227385B (zh) 核酸分子及其用于非病毒基因疗法的用途
CN115335529A (zh) 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
CN109071633A (zh) 基于使用表达增强性基因座来制备抗体的组合物和方法
TW202317753A (zh) 經武裝之嵌合受體及其使用方法
KR20230023641A (ko) Gjb2-연관 난청을 치료하기 위한 조성물 및 방법
CN109195986A (zh) 基于使用表达增强性基因座来制备抗体的组合物和方法
CN113106124B (zh) 表达cyp4v2的aav载体及其用途
US20240033325A1 (en) Treatment of danon disease
CN114350710A (zh) 编码vegf拮抗剂的多核苷酸表达盒、重组病毒及相关应用
KR20190096329A (ko) 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
KR20240021799A (ko) 청력 손실을 치료하기 위한 유전자 치료 전달 조성물 및 방법
KR20230069157A (ko) GJB2를 코딩하는 재조합 아데노 연관 바이러스 (rAAV) 및 그의 용도
CN114250227B (zh) 用于高水平表达外源基因的表达载体
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
KR20230117179A (ko) 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법
KR20220131522A (ko) 완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
CN116829722A (zh) 用于递送kh902(康柏西普)的腺相关病毒及其用途
CN112342228A (zh) 表达抗vegf融合蛋白的aav病毒载体及其应用
HK40101266A (zh) 用於递送kh902(康柏西普)的腺相关病毒及其用途
CN114250226A (zh) 用于高水平表达外源基因的表达载体
CN116457373A (zh) 用于眼部适应症的载体化TNF-α拮抗剂
NL2022714B1 (en) Optimised RAG1 deficient SCID Gene Therapy
CN116997657A (zh) 编码GJB2的重组腺相关病毒(rAAV)及其用途
KR20230041965A (ko) Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240830

Comment text: Request for Examination of Application